Valerio Zoli
Overview
Explore the profile of Valerio Zoli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rigacci L, Battistini R, Kovalchuk S, Zoli V, Puccini B, Evangelista A, et al.
Hematol Oncol
. 2022 May;
40(4):609-616.
PMID: 35612350
Salvage immunochemotherapy and transplant consolidation is the standard treatment for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We tested a combination of Obinutuzumab and DHAP for treating R/R...
2.
Pellicelli A, Giannelli V, Zoli V, Regine G, Cortese A, Ettorre G, et al.
Oxf Med Case Reports
. 2021 May;
2021(5):omab022.
PMID: 34055359
The favorable impact of antiviral therapy on low-grade hepatitis C virus (HCV)-related non-Hodgkin lymphoma manifesting as marginal zone lymphoma (MZL) has been reported in some clinical studies. However, primary HCV-related...
3.
Romano A, Pavoni C, Di Raimondo F, Tarella C, Viviani S, Rossi A, et al.
Cancer Med
. 2020 Nov;
9(23):8735-8746.
PMID: 33155754
Background: The neutrophil to lymphocyte ratio (NLR) and the lymphocyte to monocyte ratio (LMR) can reflect both the myeloid dysfunction and T-cell immune suppression and have prognostic significance. Methods: In...
4.
Santopietro M, Kovalchuk S, Battistini R, Puccini B, Annibali O, Romano I, et al.
Eur J Haematol
. 2020 Aug;
106(1):49-57.
PMID: 32779796
Objectives: To define the outcome and optimal treatment strategies in PPL. Methods: We reviewed the medical records of 49 patients with PPL treated in three Italian Hematological Institutions between 2002...
5.
Bruna R, Benedetti F, Boccomini C, Patti C, Barbui A, Pulsoni A, et al.
Haematologica
. 2019 Nov;
104(11):2241-2248.
PMID: 31666344
A prospective trial conducted in the period 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (R-HDS) conventional chemotherapy with rituximab (CHOP-R) as first-line therapy in 134...
6.
Antiviral therapy in hepatitis C-infected patients prevents relapse of diffuse large B cell lymphoma
Pellicelli A, Giannelli V, Zoli V, Pellicelli V, Zignego A
Clin Exp Hepatol
. 2018 Oct;
4(3):197-200.
PMID: 30324145
Introduction: Hepatitis C infection (HCV) is highly prevalent worldwide and has a well-known association with B-cell lymphoid malignancies. While several studies have demonstrated that antiviral therapy (AT) is effective to...
7.
Cox M, Musuraca G, Battistini R, Casaroli I, Zoli V, Anticoli-Borza P, et al.
Br J Haematol
. 2017 Dec;
183(5):819-822.
PMID: 29193017
No abstract available.
8.
Cortelazzo S, Tarella C, Massimo Gianni A, Ladetto M, Barbui A, Rossi A, et al.
J Clin Oncol
. 2017 Feb;
34(33):4015-4022.
PMID: 28199143
Purpose The benefit of high-dose chemotherapy with autologous stem-cell transplantation (ASCT) as first-line treatment in patients with diffuse large B-cell lymphomas is still a matter of debate. To address this...
9.
Pellicelli A, Marignani M, Zoli V, Romano M, Morrone A, Nosotti L, et al.
World J Hepatol
. 2011 Nov;
3(11):278-84.
PMID: 22125661
Aim: To evaluate if indolent B cell-non Hodgkin's lymphoma (B-NHL) and diffuse large B-cell lymphoma (DLBCL) in hepatitis C virus (HCV) positive patients could have different biological and clinical characteristics...
10.